https://www.nasdaq.com/press-release/fda-grants-regenerative-medicine-advanced-therapy-rmat-designation-to-allovirs
https://www.nasdaq.com/press-release/allovir-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference-2022-01-03
https://www.nasdaq.com/press-release/allovir-announces-departure-of-chief-medical-officer-augustin-melian-2021-12-16
https://www.nasdaq.com/press-release/allovir-announces-positive-preliminary-data-from-the-ongoing-phase-2-posoleucel-multi
https://www.nasdaq.com/press-release/allovir-to-host-virtual-investor-event-2021-12-02
https://www.nasdaq.com/press-release/allovir-to-participate-in-the-piper-sandler-33rd-annual-virtual-healthcare-conference
https://www.nasdaq.com/press-release/allovir-reports-third-quarter-2021-financial-results-2021-11-05
https://www.nasdaq.com/press-release/fda-grants-orphan-drug-designation-odd-to-allovirs-posoleucel-an-allogeneic-off-the
https://www.nasdaq.com/press-release/data-presented-at-idweektm-2021-demonstrate-that-alvr109-allovirs-investigational
https://www.nasdaq.com/press-release/allovir-to-present-at-the-morgan-stanley-19th-annual-global-healthcare-conference
https://www.nasdaq.com/press-release/allovir-reports-second-quarter-2021-financial-results-2021-08-06
https://www.nasdaq.com/press-release/allovir-reports-first-quarter-2021-financial-results-2021-05-06
https://www.nasdaq.com/press-release/allovir-appoints-diana-m.-brainard-m.d.-as-chief-executive-officer-effective-may-17
https://www.nasdaq.com/press-release/allovir-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/allovir-research-presented-at-the-2021-transplantation-cellular-therapy-meeting
https://www.nasdaq.com/press-release/allovir-reports-full-year-2020-financial-results-2021-02-11
https://www.nasdaq.com/press-release/allovir-announces-data-presentations-at-the-2021-transplantation-cellular-therapy
https://www.nasdaq.com/press-release/allovir-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-2021-01-04
https://www.nasdaq.com/press-release/allovir-announces-fda-clearance-of-investigational-new-drug-application-for-alvr106
https://www.nasdaq.com/press-release/company-profile-for-allovir-2020-12-10
https://www.nasdaq.com/press-release/positive-phase-2-proof-of-concept-data-for-viralym-m-and-burden-of-disease-data
https://www.nasdaq.com/press-release/preclinical-data-demonstrate-anti-viral-activity-of-allovirs-alvr109-an-allogeneic
https://www.nasdaq.com/press-release/allovir-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference
https://www.nasdaq.com/press-release/allovir-reports-third-quarter-2020-financial-results-2020-11-10
https://www.nasdaq.com/press-release/allovir-announces-oral-data-presentations-at-62nd-american-society-of-hematology
https://www.nasdaq.com/press-release/data-to-be-presented-at-idweektm-2020-demonstrate-the-economic-and-clinical-burden-of
https://www.nasdaq.com/press-release/allovir-announces-the-fda-clearance-of-investigational-new-drug-application-ind-for
https://www.nasdaq.com/press-release/allovir-appoints-ercem-atillasoy-m.d.-as-chief-regulatory-and-safety-officer-2020-09
